News | December 19, 2025
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Subscribe To Our Newsletter & Stay Updated
